NasdaqGM - Nasdaq Real Time Price USD

Clearside Biomedical, Inc. (CLSD)

0.9296

-0.0504

(-5.14%)

At close: January 13 at 4:00:01 PM EST

Clearside announces publication of insights on drug development, regulation

Clearside Biomedical (CLSD) announced that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong. The article, which was published in December 2024 by Eye and Nature.com, provides a comprehensive overview of

TipRanks 24 days ago

CLSD
-5.14%
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock

Clearside Biomedical: Strong Buy Ratings Back Pipeline Growth and Expanding Partnerships

GuruFocus.com 25 days ago

CLSD
-5.14%
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Me

GlobeNewswire 25 days ago

CLSD
-5.14%
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now

Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks last month

CLSD
-5.14%
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside’s Pipeline Programs and Suprachoroidal Delivery Technology - - Oral Presentations Delivered on ODYSSEY Wet AMD Topline Results – ALPHARETTA, Ga., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the b

GlobeNewswire last month

CLSD
-5.14%
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

CLSD
-5.14%
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations

Clearside Biomedical ( NASDAQ:CLSD ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.04m (up 21% from 3Q...

Simply Wall St. last month

CLSD
-5.14%
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...

Clearside Biomedical Inc (CLSD) advances its wet AMD program with positive trial outcomes, while navigating financial and regulatory challenges.

GuruFocus.com 2 months ago

CLSD
-5.14%
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 310.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CLSD
-5.14%
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside’s Suprachoroidal Platform - - Comp

GlobeNewswire 2 months ago

CLSD
-5.14%
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years

It's nice to see the Clearside Biomedical, Inc. ( NASDAQ:CLSD ) share price up 13% in a week. But that doesn't change...

Simply Wall St. 2 months ago

CLSD
-5.14%
Santen, Arctic Vision sign deal for ARVN001 to treat UME

Under the agreement, Arctic Vision will receive up to $85m in upfront and milestone payments.

Pharmaceutical Technology 2 months ago

SNPHY

CLSD
-5.14%
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS®) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company’s Asia-Pacific p

GlobeNewswire 2 months ago

CLSD
-5.14%
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, Novembe

GlobeNewswire 2 months ago

CLSD
-5.14%
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside’s Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. Georg

GlobeNewswire 2 months ago

CLSD
-5.14%
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora

GlobeNewswire 2 months ago

CLSD
-5.14%
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Versatility of SCS Microinjector® Featured in Multiple Presentations - ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye thro

GlobeNewswire 2 months ago

CLSD
-5.14%
Morning Movers: Arcadium Lithium surges after deal to be acquired

Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Arcadium Lithium (ALTM) up 30% after Rio Tinto (RIO) and the company announced a definitive agreement under which Rio Tinto will acquire Arcadium in an all-cash transaction for $5.85 per share Clearside Biomedical (CLSD) up 10% after announcing that the ODYSSEY Phase 2b clinical trial of CLS-AX, or axitinib injectable suspension, for the treatment of neovascular age-related macular degeneration achieved bo

TipRanks 3 months ago

ALTM

ARLTF

BA
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study

On Wednesday, Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that the ODYSSEY Phase 2b trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD) achieved both its primary and secondary outcomes. In participants who received CLS-AX delivered suprachoroidally, best corrected visual acuity (BCVA) and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept. Also Read: Why Is Clearsi

Benzinga 3 months ago

CLSD
-5.14%
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D., MBA - ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE NEWSWI

GlobeNewswire 3 months ago

CLSD
-5.14%

Performance Overview

Return	CLSD	S&P 500
YTD	-6.57%	-1.20%
1-Year	-35.89%	+22.00%
3-Year	-60.10%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Clearside Biomedical, Inc. (CLSD)

Clearside announces publication of insights on drug development, regulation

Analyst Sees 500% Upside for This Pharmaceutical Penny Stock

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy

Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations

Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years

Santen, Arctic Vision sign deal for ARVN001 to treat UME

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Morning Movers: Arcadium Lithium surges after deal to be acquired

Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Performance Overview